English
简体中文
Total: £ 56.28
Published Date: 2026-01-08 | Pages: 133 | Tables: 129 | Pharma & Healthcare
The global Personalized Cancer Medicine market was valued at US$ 214017 million in 2025 and is anticipated to reach US$ 482388 million by 2032, at a CAGR of 12.5% from 2026 to 2032.
Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.
Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.
Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.The average gross profit margin of this product is 78%.
Opportunities are driven by the higher response certainty enabled by biomarker-guided therapy and the forward shift of decision-making pathways. As broad molecular profiling and CDx become more embedded in routine practice, treatment selection increasingly moves from organ-based empiricism to molecular stratification, enabling better-matched first-line choices. Tumor-agnostic development further expands markets from “by organ” to “by target/biology,” increasing label-extension potential. Strengthening guideline and real-world consensus on “test first, treat next” supports synchronized growth of testing penetration and prescription accessibility.
Key constraints include evidence thresholds, stratification complexity, and payer sustainability. Biomarkers are not static—tumor heterogeneity, resistance evolution, and testing variability complicate population definition and benefit extrapolation. When access is CDx-dependent, drug and diagnostic registration, supply, and clinical pathways must move in lockstep; otherwise, “drug-ready but test-not-ready” bottlenecks emerge. In parallel, precision regimens often require more sophisticated management (AE handling, combinations, sequencing), raising the bar for standardized quality governance; without clear value evidence and coverage mechanisms, adoption cadence can fluctuate.
Demand is evolving from “finding an actionable target” to “full-cycle precision management.” Broad NGS and CDx are moving earlier in the disease course, refining perioperative and adjuvant decisions. Meanwhile, ctDNA/MRD-driven monitoring is gaining clinical relevance, enabling more real-time relapse-risk assessment, response evaluation, and resistance-mechanism identification—powering closed-loop “test–treat–retest” workflows. Providers increasingly pursue platformized capabilities that integrate molecular pathology, pharmacy governance, imaging, and longitudinal follow-up to build replicable precision-oncology systems and improve multidisciplinary efficiency and patient experience.
Upstream resembles a multi-technology biopharma supply chain. Small-molecule targeted drugs depend on key intermediates, chiral inputs, and high-purity solvent systems, with impurity control and scale-up consistency as the core. Biologics and ADCs rely on cell-line development, media/feed, single-use bioprocess systems, chromatography resins and filtration consumables, plus high-barrier linkers/payloads with stable supply. Cell and gene therapies extend further to plasmids, viral-vector inputs, cell-culture materials, and closed-system manufacturing consumables. As drugs become tightly coupled with diagnostics, upstream quality systems must also align with testing workflows (specimens, reference materials, and QA), making supply continuity and disciplined change control central to regulatory maintenance, commercialization ramp, and global delivery resilience.
This report delivers a comprehensive overview of the global Personalized Cancer Medicine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Personalized Cancer Medicine. The Personalized Cancer Medicine market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Personalized Cancer Medicine market comprehensively. Regional market sizes by Method, by Application, by Route of Administration, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Personalized Cancer Medicine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Method, by Application, and by region.
Market Segmentation
By Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Segment by Method
Cancer Immunotherapy
Targeted Therapy
Segment by Route of Administration
Injection
Oral
Other
Segment by Therapeutic Modality
Small-molecule Targeted Therapies
Antibody Therapies
Biomarker-guided Checkpoint Inhibitors
Antibody–drug Conjugates
Cell & Gene Therapies
Segment by Application
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Method, by Application, by Route of Administration, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Personalized Cancer Medicine companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Method, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Method
1.2.1 Global Personalized Cancer Medicine Market Size Growth Rate by Method: 2021 vs 2025 vs 2032
1.2.2 Cancer Immunotherapy
1.2.3 Targeted Therapy
1.3 Market by Route of Administration
1.3.1 Global Personalized Cancer Medicine Market Size Growth Rate by Route of Administration: 2021 vs 2025 vs 2032
1.3.2 Injection
1.3.3 Oral
1.3.4 Other
1.4 Market by Therapeutic Modality
1.4.1 Global Personalized Cancer Medicine Market Size Growth Rate by Therapeutic Modality: 2021 vs 2025 vs 2032
1.4.2 Small-molecule Targeted Therapies
1.4.3 Antibody Therapies
1.4.4 Biomarker-guided Checkpoint Inhibitors
1.4.5 Antibody–drug Conjugates
1.4.6 Cell & Gene Therapies
1.5 Market by Application
1.5.1 Global Personalized Cancer Medicine Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Lung Cancer
1.5.3 Breast Cancer
1.5.4 Prostate Cancer
1.5.5 Blood-related Cancer
1.5.6 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Personalized Cancer Medicine Market Perspective (2021–2032)
2.2 Global Personalized Cancer Medicine Growth Trends by Region
2.2.1 Global Personalized Cancer Medicine Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Personalized Cancer Medicine Historic Market Size by Region (2021–2026)
2.2.3 Personalized Cancer Medicine Forecasted Market Size by Region (2027–2032)
2.3 Personalized Cancer Medicine Market Dynamics
2.3.1 Personalized Cancer Medicine Industry Trends
2.3.2 Personalized Cancer Medicine Market Drivers
2.3.3 Personalized Cancer Medicine Market Challenges
2.3.4 Personalized Cancer Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalized Cancer Medicine Players by Revenue
3.1.1 Global Top Personalized Cancer Medicine Players by Revenue (2021–2026)
3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2021–2026)
3.2 Global Top Personalized Cancer Medicine Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Personalized Cancer Medicine Revenue
3.4 Global Personalized Cancer Medicine Market Concentration Ratio
3.4.1 Global Personalized Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalized Cancer Medicine Revenue in 2025
3.5 Global Key Players of Personalized Cancer Medicine Head Offices and Areas Served
3.6 Global Key Players of Personalized Cancer Medicine, Products and Applications
3.7 Global Key Players of Personalized Cancer Medicine, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Personalized Cancer Medicine Breakdown Data by Method
4.1 Global Personalized Cancer Medicine Historic Market Size by Method (2021–2026)
4.2 Global Personalized Cancer Medicine Forecasted Market Size by Method (2027–2032)
5 Personalized Cancer Medicine Breakdown Data by Application
5.1 Global Personalized Cancer Medicine Historic Market Size by Application (2021–2026)
5.2 Global Personalized Cancer Medicine Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Personalized Cancer Medicine Market Size (2021–2032)
6.2 North America Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Personalized Cancer Medicine Market Size by Country (2021–2026)
6.4 North America Personalized Cancer Medicine Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Personalized Cancer Medicine Market Size (2021–2032)
7.2 Europe Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Personalized Cancer Medicine Market Size by Country (2021–2026)
7.4 Europe Personalized Cancer Medicine Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Personalized Cancer Medicine Market Size (2021–2032)
8.2 Asia-Pacific Personalized Cancer Medicine Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2021–2026)
8.4 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Personalized Cancer Medicine Market Size (2021–2032)
9.2 Latin America Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Personalized Cancer Medicine Market Size by Country (2021–2026)
9.4 Latin America Personalized Cancer Medicine Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalized Cancer Medicine Market Size (2021–2032)
10.2 Middle East & Africa Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2021–2026)
10.4 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Personalized Cancer Medicine Introduction
11.1.4 AbbVie Revenue in Personalized Cancer Medicine Business (2021–2026)
11.1.5 AbbVie Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Details
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Personalized Cancer Medicine Introduction
11.2.4 Johnson & Johnson Revenue in Personalized Cancer Medicine Business (2021–2026)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalized Cancer Medicine Introduction
11.3.4 Novartis Revenue in Personalized Cancer Medicine Business (2021–2026)
11.3.5 Novartis Recent Development
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Details
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Personalized Cancer Medicine Introduction
11.4.4 Gilead Sciences Revenue in Personalized Cancer Medicine Business (2021–2026)
11.4.5 Gilead Sciences Recent Development
11.5 Roche
11.5.1 Roche Company Details
11.5.2 Roche Business Overview
11.5.3 Roche Personalized Cancer Medicine Introduction
11.5.4 Roche Revenue in Personalized Cancer Medicine Business (2021–2026)
11.5.5 Roche Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Details
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Introduction
11.6.4 Bristol-Myers Squibb Revenue in Personalized Cancer Medicine Business (2021–2026)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Personalized Cancer Medicine Introduction
11.7.4 Amgen Revenue in Personalized Cancer Medicine Business (2021–2026)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Personalized Cancer Medicine Introduction
11.8.4 AstraZeneca Revenue in Personalized Cancer Medicine Business (2021–2026)
11.8.5 AstraZeneca Recent Development
11.9 Merck & Co
11.9.1 Merck & Co Company Details
11.9.2 Merck & Co Business Overview
11.9.3 Merck & Co Personalized Cancer Medicine Introduction
11.9.4 Merck & Co Revenue in Personalized Cancer Medicine Business (2021–2026)
11.9.5 Merck & Co Recent Development
11.10 Takeda
11.10.1 Takeda Company Details
11.10.2 Takeda Business Overview
11.10.3 Takeda Personalized Cancer Medicine Introduction
11.10.4 Takeda Revenue in Personalized Cancer Medicine Business (2021–2026)
11.10.5 Takeda Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Details
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Personalized Cancer Medicine Introduction
11.11.4 Merck KGaA Revenue in Personalized Cancer Medicine Business (2021–2026)
11.11.5 Merck KGaA Recent Development
11.12 Seagen
11.12.1 Seagen Company Details
11.12.2 Seagen Business Overview
11.12.3 Seagen Personalized Cancer Medicine Introduction
11.12.4 Seagen Revenue in Personalized Cancer Medicine Business (2021–2026)
11.12.5 Seagen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Personalized Cancer Medicine Introduction
11.13.4 Eli Lilly Revenue in Personalized Cancer Medicine Business (2021–2026)
11.13.5 Eli Lilly Recent Development
11.14 Ono Pharmaceutical
11.14.1 Ono Pharmaceutical Company Details
11.14.2 Ono Pharmaceutical Business Overview
11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Introduction
11.14.4 Ono Pharmaceutical Revenue in Personalized Cancer Medicine Business (2021–2026)
11.14.5 Ono Pharmaceutical Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Details
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Personalized Cancer Medicine Introduction
11.15.4 Pfizer Revenue in Personalized Cancer Medicine Business (2021–2026)
11.15.5 Pfizer Recent Development
11.16 GSK
11.16.1 GSK Company Details
11.16.2 GSK Business Overview
11.16.3 GSK Personalized Cancer Medicine Introduction
11.16.4 GSK Revenue in Personalized Cancer Medicine Business (2021–2026)
11.16.5 GSK Recent Development
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Personalized Cancer Medicine Introduction
11.17.4 Exelixis Revenue in Personalized Cancer Medicine Business (2021–2026)
11.17.5 Exelixis Recent Development
11.18 Regeneron
11.18.1 Regeneron Company Details
11.18.2 Regeneron Business Overview
11.18.3 Regeneron Personalized Cancer Medicine Introduction
11.18.4 Regeneron Revenue in Personalized Cancer Medicine Business (2021–2026)
11.18.5 Regeneron Recent Development
11.19 Innovent
11.19.1 Innovent Company Details
11.19.2 Innovent Business Overview
11.19.3 Innovent Personalized Cancer Medicine Introduction
11.19.4 Innovent Revenue in Personalized Cancer Medicine Business (2021–2026)
11.19.5 Innovent Recent Development
11.20 Hengrui Medicine
11.20.1 Hengrui Medicine Company Details
11.20.2 Hengrui Medicine Business Overview
11.20.3 Hengrui Medicine Personalized Cancer Medicine Introduction
11.20.4 Hengrui Medicine Revenue in Personalized Cancer Medicine Business (2021–2026)
11.20.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Personalized Cancer Medicine Market Size Growth Rate by Method (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Cancer Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Global Personalized Cancer Medicine Market Size Growth Rate by Route of Administration (US$ Million): 2021 vs 2025 vs 2032
Table 5. Key Players of Injection
Table 6. Key Players of Oral
Table 7. Key Players of Other
Table 8. Global Personalized Cancer Medicine Market Size Growth Rate by Therapeutic Modality (US$ Million): 2021 vs 2025 vs 2032
Table 9. Key Players of Small-molecule Targeted Therapies
Table 10. Key Players of Antibody Therapies
Table 11. Key Players of Biomarker-guided Checkpoint Inhibitors
Table 12. Key Players of Antibody–drug Conjugates
Table 13. Key Players of Cell & Gene Therapies
Table 14. Global Personalized Cancer Medicine Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Personalized Cancer Medicine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 16. Global Personalized Cancer Medicine Market Size by Region (US$ Million), 2021–2026
Table 17. Global Personalized Cancer Medicine Market Share by Region (2021–2026)
Table 18. Global Personalized Cancer Medicine Forecasted Market Size by Region (US$ Million), 2027–2032
Table 19. Global Personalized Cancer Medicine Market Share by Region (2027–2032)
Table 20. Personalized Cancer Medicine Market Trends
Table 21. Personalized Cancer Medicine Market Drivers
Table 22. Personalized Cancer Medicine Market Challenges
Table 23. Personalized Cancer Medicine Market Restraints
Table 24. Global Personalized Cancer Medicine Revenue by Players (US$ Million), 2021–2026
Table 25. Global Personalized Cancer Medicine Market Share by Players (2021–2026)
Table 26. Global Top Personalized Cancer Medicine Players by Tier (Tier 1, Tier 2, and Tier 3), based on Personalized Cancer Medicine Revenue, 2025
Table 27. Ranking of Global Top Personalized Cancer Medicine Companies by Revenue (US$ Million) in 2025
Table 28. Global 5 Largest Players Market Share by Personalized Cancer Medicine Revenue (CR5 and HHI), 2021–2026
Table 29. Global Key Players of Personalized Cancer Medicine, Headquarters and Area Served
Table 30. Global Key Players of Personalized Cancer Medicine, Products and Applications
Table 31. Global Key Players of Personalized Cancer Medicine, Date of General Availability (GA)
Table 32. Mergers and Acquisitions, Expansion Plans
Table 33. Global Personalized Cancer Medicine Market Size by Method (US$ Million), 2021–2026
Table 34. Global Personalized Cancer Medicine Revenue Market Share by Method (2021–2026)
Table 35. Global Personalized Cancer Medicine Forecasted Market Size by Method (US$ Million), 2027–2032
Table 36. Global Personalized Cancer Medicine Revenue Market Share by Method (2027–2032)
Table 37. Global Personalized Cancer Medicine Market Size by Application (US$ Million), 2021–2026
Table 38. Global Personalized Cancer Medicine Revenue Market Share by Application (2021–2026)
Table 39. Global Personalized Cancer Medicine Forecasted Market Size by Application (US$ Million), 2027–2032
Table 40. Global Personalized Cancer Medicine Revenue Market Share by Application (2027–2032)
Table 41. North America Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. North America Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026
Table 43. North America Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032
Table 44. Europe Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Europe Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026
Table 46. Europe Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032
Table 47. Asia-Pacific Personalized Cancer Medicine Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 48. Asia-Pacific Personalized Cancer Medicine Market Size by Region (US$ Million), 2021–2026
Table 49. Asia-Pacific Personalized Cancer Medicine Market Size by Region (US$ Million), 2027–2032
Table 50. Latin America Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 51. Latin America Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026
Table 52. Latin America Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032
Table 53. Middle East & Africa Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 54. Middle East & Africa Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026
Table 55. Middle East & Africa Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032
Table 56. AbbVie Company Details
Table 57. AbbVie Business Overview
Table 58. AbbVie Personalized Cancer Medicine Product
Table 59. AbbVie Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 60. AbbVie Recent Development
Table 61. Johnson & Johnson Company Details
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Personalized Cancer Medicine Product
Table 64. Johnson & Johnson Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 65. Johnson & Johnson Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Personalized Cancer Medicine Product
Table 69. Novartis Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 70. Novartis Recent Development
Table 71. Gilead Sciences Company Details
Table 72. Gilead Sciences Business Overview
Table 73. Gilead Sciences Personalized Cancer Medicine Product
Table 74. Gilead Sciences Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 75. Gilead Sciences Recent Development
Table 76. Roche Company Details
Table 77. Roche Business Overview
Table 78. Roche Personalized Cancer Medicine Product
Table 79. Roche Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 80. Roche Recent Development
Table 81. Bristol-Myers Squibb Company Details
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Personalized Cancer Medicine Product
Table 84. Bristol-Myers Squibb Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 85. Bristol-Myers Squibb Recent Development
Table 86. Amgen Company Details
Table 87. Amgen Business Overview
Table 88. Amgen Personalized Cancer Medicine Product
Table 89. Amgen Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 90. Amgen Recent Development
Table 91. AstraZeneca Company Details
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Personalized Cancer Medicine Product
Table 94. AstraZeneca Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 95. AstraZeneca Recent Development
Table 96. Merck & Co Company Details
Table 97. Merck & Co Business Overview
Table 98. Merck & Co Personalized Cancer Medicine Product
Table 99. Merck & Co Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 100. Merck & Co Recent Development
Table 101. Takeda Company Details
Table 102. Takeda Business Overview
Table 103. Takeda Personalized Cancer Medicine Product
Table 104. Takeda Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 105. Takeda Recent Development
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Personalized Cancer Medicine Product
Table 109. Merck KGaA Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 110. Merck KGaA Recent Development
Table 111. Seagen Company Details
Table 112. Seagen Business Overview
Table 113. Seagen Personalized Cancer Medicine Product
Table 114. Seagen Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 115. Seagen Recent Development
Table 116. Eli Lilly Company Details
Table 117. Eli Lilly Business Overview
Table 118. Eli Lilly Personalized Cancer Medicine Product
Table 119. Eli Lilly Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 120. Eli Lilly Recent Development
Table 121. Ono Pharmaceutical Company Details
Table 122. Ono Pharmaceutical Business Overview
Table 123. Ono Pharmaceutical Personalized Cancer Medicine Product
Table 124. Ono Pharmaceutical Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 125. Ono Pharmaceutical Recent Development
Table 126. Pfizer Company Details
Table 127. Pfizer Business Overview
Table 128. Pfizer Personalized Cancer Medicine Product
Table 129. Pfizer Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 130. Pfizer Recent Development
Table 131. GSK Company Details
Table 132. GSK Business Overview
Table 133. GSK Personalized Cancer Medicine Product
Table 134. GSK Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 135. GSK Recent Development
Table 136. Exelixis Company Details
Table 137. Exelixis Business Overview
Table 138. Exelixis Personalized Cancer Medicine Product
Table 139. Exelixis Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 140. Exelixis Recent Development
Table 141. Regeneron Company Details
Table 142. Regeneron Business Overview
Table 143. Regeneron Personalized Cancer Medicine Product
Table 144. Regeneron Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 145. Regeneron Recent Development
Table 146. Innovent Company Details
Table 147. Innovent Business Overview
Table 148. Innovent Personalized Cancer Medicine Product
Table 149. Innovent Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 150. Innovent Recent Development
Table 151. Hengrui Medicine Company Details
Table 152. Hengrui Medicine Business Overview
Table 153. Hengrui Medicine Personalized Cancer Medicine Product
Table 154. Hengrui Medicine Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026
Table 155. Hengrui Medicine Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
Table 159. Authors List of This Report
List of Figures
Figure 1. Personalized Cancer Medicine Picture
Figure 2. Global Personalized Cancer Medicine Market Size Comparison by Method (US$ Million), 2021–2032
Figure 3. Global Personalized Cancer Medicine Market Share by Method: 2025 vs 2032
Figure 4. Cancer Immunotherapy Features
Figure 5. Targeted Therapy Features
Figure 6. Global Personalized Cancer Medicine Market Size Comparison by Route of Administration (US$ Million), 2021–2032
Figure 7. Injection Features
Figure 8. Oral Features
Figure 9. Other Features
Figure 10. Global Personalized Cancer Medicine Market Size Comparison by Therapeutic Modality (US$ Million), 2021–2032
Figure 11. Small-molecule Targeted Therapies Features
Figure 12. Antibody Therapies Features
Figure 13. Biomarker-guided Checkpoint Inhibitors Features
Figure 14. Antibody–drug Conjugates Features
Figure 15. Cell & Gene Therapies Features
Figure 16. Global Personalized Cancer Medicine Market Size by Application (US$ Million), 2021–2032
Figure 17. Global Personalized Cancer Medicine Market Share by Application: 2025 vs 2032
Figure 18. Lung Cancer Case Studies
Figure 19. Breast Cancer Case Studies
Figure 20. Prostate Cancer Case Studies
Figure 21. Blood-related Cancer Case Studies
Figure 22. Other Case Studies
Figure 23. Personalized Cancer Medicine Report Years Considered
Figure 24. Global Personalized Cancer Medicine Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 25. Global Personalized Cancer Medicine Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Personalized Cancer Medicine Market Share by Region: 2025 vs 2032
Figure 27. Global Personalized Cancer Medicine Market Share by Players in 2025
Figure 28. Global Personalized Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 29. The Top 10 and 5 Players Market Share by Personalized Cancer Medicine Revenue in 2025
Figure 30. North America Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. North America Personalized Cancer Medicine Market Share by Country (2021–2032)
Figure 32. United States Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Canada Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Europe Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Europe Personalized Cancer Medicine Market Share by Country (2021–2032)
Figure 36. Germany Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. France Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. U.K. Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Italy Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Russia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Ireland Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Asia-Pacific Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Asia-Pacific Personalized Cancer Medicine Market Share by Region (2021–2032)
Figure 44. China Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Japan Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. South Korea Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Southeast Asia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. India Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Australia & New Zealand Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Latin America Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Latin America Personalized Cancer Medicine Market Share by Country (2021–2032)
Figure 52. Mexico Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Brazil Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Middle East & Africa Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Middle East & Africa Personalized Cancer Medicine Market Share by Country (2021–2032)
Figure 56. Israel Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Saudi Arabia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 58. UAE Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032
Figure 59. AbbVie Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 60. Johnson & Johnson Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 61. Novartis Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 62. Gilead Sciences Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 63. Roche Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 65. Amgen Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 66. AstraZeneca Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 67. Merck & Co Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 68. Takeda Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 69. Merck KGaA Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 70. Seagen Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 71. Eli Lilly Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 72. Ono Pharmaceutical Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 73. Pfizer Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 74. GSK Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 75. Exelixis Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 76. Regeneron Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 77. Innovent Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 78. Hengrui Medicine Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
